JP6092870B2 - メタ置換ビフェニル末梢に限局されたfaah阻害剤 - Google Patents
メタ置換ビフェニル末梢に限局されたfaah阻害剤 Download PDFInfo
- Publication number
- JP6092870B2 JP6092870B2 JP2014526261A JP2014526261A JP6092870B2 JP 6092870 B2 JP6092870 B2 JP 6092870B2 JP 2014526261 A JP2014526261 A JP 2014526261A JP 2014526261 A JP2014526261 A JP 2014526261A JP 6092870 B2 JP6092870 B2 JP 6092870B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- alkyl
- faah
- compound according
- pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003940 fatty acid amidase inhibitor Substances 0.000 title description 41
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical class C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 title description 6
- 235000010290 biphenyl Nutrition 0.000 title description 3
- 239000004305 biphenyl Substances 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 142
- 208000002193 Pain Diseases 0.000 claims description 66
- 102100029111 Fatty-acid amide hydrolase 1 Human genes 0.000 claims description 64
- 108010046094 fatty-acid amide hydrolase Proteins 0.000 claims description 64
- 230000036407 pain Effects 0.000 claims description 64
- 150000002148 esters Chemical class 0.000 claims description 58
- 239000000203 mixture Substances 0.000 claims description 53
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 claims description 46
- LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 claims description 42
- 239000001257 hydrogen Substances 0.000 claims description 39
- 229910052739 hydrogen Inorganic materials 0.000 claims description 39
- 239000008194 pharmaceutical composition Substances 0.000 claims description 38
- 230000004054 inflammatory process Effects 0.000 claims description 35
- 206010061218 Inflammation Diseases 0.000 claims description 34
- 230000002093 peripheral effect Effects 0.000 claims description 34
- 208000027418 Wounds and injury Diseases 0.000 claims description 31
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 27
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 27
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 27
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 26
- -1 tetrahydropyran-4-yl Chemical group 0.000 claims description 26
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 25
- 238000011282 treatment Methods 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 20
- 230000006378 damage Effects 0.000 claims description 19
- 208000014674 injury Diseases 0.000 claims description 18
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 12
- 230000035876 healing Effects 0.000 claims description 12
- 230000005764 inhibitory process Effects 0.000 claims description 11
- HXYVTAGFYLMHSO-UHFFFAOYSA-N palmitoyl ethanolamide Chemical compound CCCCCCCCCCCCCCCC(=O)NCCO HXYVTAGFYLMHSO-UHFFFAOYSA-N 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 229950007031 palmidrol Drugs 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 208000024891 symptom Diseases 0.000 claims description 8
- 208000037816 tissue injury Diseases 0.000 claims description 8
- BOWVQLFMWHZBEF-KTKRTIGZSA-N oleoyl ethanolamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)NCCO BOWVQLFMWHZBEF-KTKRTIGZSA-N 0.000 claims description 7
- 230000001965 increasing effect Effects 0.000 claims description 6
- 230000029663 wound healing Effects 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
- 210000001044 sensory neuron Anatomy 0.000 claims description 5
- 206010011224 Cough Diseases 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- 206010020853 Hypertonic bladder Diseases 0.000 claims description 4
- 206010028116 Mucosal inflammation Diseases 0.000 claims description 4
- 201000010927 Mucositis Diseases 0.000 claims description 4
- 201000009053 Neurodermatitis Diseases 0.000 claims description 4
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims description 4
- 230000009390 immune abnormality Effects 0.000 claims description 4
- 208000020629 overactive bladder Diseases 0.000 claims description 4
- OTGQIQQTPXJQRG-UHFFFAOYSA-N N-(octadecanoyl)ethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCCO OTGQIQQTPXJQRG-UHFFFAOYSA-N 0.000 claims description 3
- 210000000936 intestine Anatomy 0.000 claims description 3
- 210000002784 stomach Anatomy 0.000 claims description 2
- 238000000034 method Methods 0.000 description 54
- 230000000694 effects Effects 0.000 description 36
- 210000004556 brain Anatomy 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 20
- 239000003814 drug Substances 0.000 description 20
- 229940079593 drug Drugs 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 18
- 125000003342 alkenyl group Chemical group 0.000 description 17
- 210000003169 central nervous system Anatomy 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 17
- 239000004480 active ingredient Substances 0.000 description 16
- 239000003557 cannabinoid Substances 0.000 description 16
- 229930003827 cannabinoid Natural products 0.000 description 16
- 206010052428 Wound Diseases 0.000 description 15
- 125000004404 heteroalkyl group Chemical group 0.000 description 15
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- 229940125904 compound 1 Drugs 0.000 description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 208000004454 Hyperalgesia Diseases 0.000 description 13
- 125000000392 cycloalkenyl group Chemical group 0.000 description 13
- 125000000753 cycloalkyl group Chemical group 0.000 description 13
- 102000005962 receptors Human genes 0.000 description 13
- 108020003175 receptors Proteins 0.000 description 13
- 150000001200 N-acyl ethanolamides Chemical class 0.000 description 12
- 229920001525 carrageenan Polymers 0.000 description 12
- 239000002621 endocannabinoid Substances 0.000 description 12
- 125000005842 heteroatom Chemical group 0.000 description 12
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 12
- 150000002431 hydrogen Chemical class 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 239000002552 dosage form Substances 0.000 description 11
- 239000003937 drug carrier Substances 0.000 description 11
- 210000002683 foot Anatomy 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- 239000003826 tablet Substances 0.000 description 11
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 10
- 108050007331 Cannabinoid receptor Proteins 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 235000010418 carrageenan Nutrition 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 10
- 235000019441 ethanol Nutrition 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 238000001990 intravenous administration Methods 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 9
- 230000003040 nociceptive effect Effects 0.000 description 9
- 238000007920 subcutaneous administration Methods 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- RCRCTBLIHCHWDZ-UHFFFAOYSA-N 2-Arachidonoyl Glycerol Chemical compound CCCCCC=CCC=CCC=CCC=CCCCC(=O)OC(CO)CO RCRCTBLIHCHWDZ-UHFFFAOYSA-N 0.000 description 8
- 208000035154 Hyperesthesia Diseases 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 208000004296 neuralgia Diseases 0.000 description 8
- 208000021722 neuropathic pain Diseases 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 8
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- CMEQHOXCIGFZNJ-UHFFFAOYSA-N [3-(3-carbamoylphenyl)-4-hydroxyphenyl] n-cyclohexylcarbamate Chemical compound NC(=O)C1=CC=CC(C=2C(=CC=C(OC(=O)NC3CCCCC3)C=2)O)=C1 CMEQHOXCIGFZNJ-UHFFFAOYSA-N 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000000679 carrageenan Substances 0.000 description 7
- 229940113118 carrageenan Drugs 0.000 description 7
- 238000013461 design Methods 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 150000004665 fatty acids Chemical class 0.000 description 7
- 229910052736 halogen Inorganic materials 0.000 description 7
- 150000002367 halogens Chemical class 0.000 description 7
- 230000007062 hydrolysis Effects 0.000 description 7
- 238000006460 hydrolysis reaction Methods 0.000 description 7
- 238000007918 intramuscular administration Methods 0.000 description 7
- 230000003902 lesion Effects 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- ROFVXGGUISEHAM-UHFFFAOYSA-N URB597 Chemical compound NC(=O)C1=CC=CC(C=2C=C(OC(=O)NC3CCCCC3)C=CC=2)=C1 ROFVXGGUISEHAM-UHFFFAOYSA-N 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 6
- XXYVIVXHJDQNDT-UHFFFAOYSA-N 3-[3,5-bis(phenylmethoxy)phenyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2C=C(OCC=3C=CC=CC=3)C=C(OCC=3C=CC=CC=3)C=2)=C1 XXYVIVXHJDQNDT-UHFFFAOYSA-N 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- 206010065390 Inflammatory pain Diseases 0.000 description 5
- 102000005398 Monoacylglycerol Lipase Human genes 0.000 description 5
- 108020002334 Monoacylglycerol lipase Proteins 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 208000004210 Pressure Ulcer Diseases 0.000 description 5
- 230000036592 analgesia Effects 0.000 description 5
- 229940035676 analgesics Drugs 0.000 description 5
- 239000000730 antalgic agent Substances 0.000 description 5
- 230000003502 anti-nociceptive effect Effects 0.000 description 5
- 230000006399 behavior Effects 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- ZVDWFQPJADEFJA-UHFFFAOYSA-N 1-bromo-3,5-bis(phenylmethoxy)benzene Chemical compound C=1C(OCC=2C=CC=CC=2)=CC(Br)=CC=1OCC1=CC=CC=C1 ZVDWFQPJADEFJA-UHFFFAOYSA-N 0.000 description 4
- KTCFCRLWFAOENY-UHFFFAOYSA-N 3-(3,5-dihydroxyphenyl)benzamide Chemical compound NC(=O)C1=CC=CC(C=2C=C(O)C=C(O)C=2)=C1 KTCFCRLWFAOENY-UHFFFAOYSA-N 0.000 description 4
- 208000028389 Nerve injury Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 229940065144 cannabinoids Drugs 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000001647 drug administration Methods 0.000 description 4
- 235000019439 ethyl acetate Nutrition 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 230000003447 ipsilateral effect Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 208000030159 metabolic disease Diseases 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 230000008764 nerve damage Effects 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 229940005483 opioid analgesics Drugs 0.000 description 4
- 229940126701 oral medication Drugs 0.000 description 4
- 230000008058 pain sensation Effects 0.000 description 4
- 210000005223 peripheral sensory neuron Anatomy 0.000 description 4
- 230000002085 persistent effect Effects 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 210000000278 spinal cord Anatomy 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 3
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 208000030814 Eating disease Diseases 0.000 description 3
- 208000004930 Fatty Liver Diseases 0.000 description 3
- 208000019454 Feeding and Eating disease Diseases 0.000 description 3
- 206010019708 Hepatic steatosis Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 102000003840 Opioid Receptors Human genes 0.000 description 3
- 108090000137 Opioid Receptors Proteins 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 235000021407 appetite control Nutrition 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 235000014632 disordered eating Nutrition 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 208000010706 fatty liver disease Diseases 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 238000013537 high throughput screening Methods 0.000 description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 3
- 230000035874 hyperreactivity Effects 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 210000000929 nociceptor Anatomy 0.000 description 3
- 108091008700 nociceptors Proteins 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011808 rodent model Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000020341 sensory perception of pain Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- LGEQQWMQCRIYKG-GJVVKNRISA-N (5Z,8Z,11Z,14Z)-2,2,3,3-tetradeuterio-N-(2-hydroxyethyl)icosa-5,8,11,14-tetraenamide Chemical compound C(C(C(C\C=C/C\C=C/C\C=C/C\C=C/CCCCC)([2H])[2H])([2H])[2H])(=O)NCCO LGEQQWMQCRIYKG-GJVVKNRISA-N 0.000 description 2
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 description 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- MVVPIAAVGAWJNQ-DOFZRALJSA-N Arachidonoyl dopamine Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCC1=CC=C(O)C(O)=C1 MVVPIAAVGAWJNQ-DOFZRALJSA-N 0.000 description 2
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 description 2
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 description 2
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 description 2
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 description 2
- 102100036214 Cannabinoid receptor 2 Human genes 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229940122746 Fatty acid amide hydrolase inhibitor Drugs 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000004157 Hydrolases Human genes 0.000 description 2
- 108090000604 Hydrolases Proteins 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 208000001294 Nociceptive Pain Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000010886 Peripheral nerve injury Diseases 0.000 description 2
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000028990 Skin injury Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000002847 Surgical Wound Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- SVYQXUKEUSEONO-UHFFFAOYSA-N [3-(3-carbamoylphenyl)-5-hydroxyphenyl] n-cyclohexylcarbamate Chemical compound NC(=O)C1=CC=CC(C=2C=C(OC(=O)NC3CCCCC3)C=C(O)C=2)=C1 SVYQXUKEUSEONO-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000012790 adhesive layer Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000001851 biosynthetic effect Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000009956 central mechanism Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 239000006274 endogenous ligand Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- BRZVRMXQCRPLQG-UHFFFAOYSA-N n-cyclohexyl-2-(3-phenylphenyl)acetamide Chemical compound C1CCCCC1NC(=O)CC(C=1)=CC=CC=1C1=CC=CC=C1 BRZVRMXQCRPLQG-UHFFFAOYSA-N 0.000 description 2
- 210000004126 nerve fiber Anatomy 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000001473 noxious effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000037324 pain perception Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 210000002248 primary sensory neuron Anatomy 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000003594 spinal ganglia Anatomy 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 2
- HHVUFQYJOSFTEH-UHFFFAOYSA-N urb602 Chemical compound C1CCCCC1OC(=O)NC(C=1)=CC=CC=1C1=CC=CC=C1 HHVUFQYJOSFTEH-UHFFFAOYSA-N 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical group O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- 150000004057 1,4-benzoquinones Chemical class 0.000 description 1
- 125000000196 1,4-pentadienyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])=C([H])[H] 0.000 description 1
- RCRCTBLIHCHWDZ-DOFZRALJSA-N 2-arachidonoylglycerol Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OC(CO)CO RCRCTBLIHCHWDZ-DOFZRALJSA-N 0.000 description 1
- UPWGQKDVAURUGE-KTKRTIGZSA-N 2-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC(CO)CO UPWGQKDVAURUGE-KTKRTIGZSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000000187 Abnormal Reflex Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000027496 Behcet disease Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 238000010152 Bonferroni least significant difference Methods 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- RSUMDJRTAFBISX-UHFFFAOYSA-N CB-13 Chemical compound C12=CC=CC=C2C(OCCCCC)=CC=C1C(=O)C1=CC=CC2=CC=CC=C12 RSUMDJRTAFBISX-UHFFFAOYSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 101710187022 Cannabinoid receptor 2 Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 102000013392 Carboxylesterase Human genes 0.000 description 1
- 108010051152 Carboxylesterase Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 206010064012 Central pain syndrome Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 208000012514 Cumulative Trauma disease Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000710899 Homo sapiens Cannabinoid receptor 1 Proteins 0.000 description 1
- 101000875075 Homo sapiens Cannabinoid receptor 2 Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027465 Metastases to skin Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 238000012565 NMR experiment Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010029174 Nerve compression Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- HBMSIPLIFIVUKZ-UHFFFAOYSA-N Palmitinsaeure-propylamid Natural products CCCCCCCCCCCCCCCC(=O)NCCC HBMSIPLIFIVUKZ-UHFFFAOYSA-N 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000009344 Penetrating Wounds Diseases 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 206010040744 Sinus headache Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 208000006045 Spondylarthropathies Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010043269 Tension headache Diseases 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- 208000005485 Thrombocytosis Diseases 0.000 description 1
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 description 1
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 1
- 206010067722 Toxic neuropathy Diseases 0.000 description 1
- 231100000126 Toxic neuropathy Toxicity 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical class [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- SQMHDUVJEGPWLM-UHFFFAOYSA-N [3-hydroxy-5-[3-(methylcarbamoyl)phenyl]phenyl] n-cyclohexylcarbamate Chemical compound CNC(=O)C1=CC=CC(C=2C=C(OC(=O)NC3CCCCC3)C=C(O)C=2)=C1 SQMHDUVJEGPWLM-UHFFFAOYSA-N 0.000 description 1
- 229940008309 acetone / ethanol Drugs 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000001197 anandamide transport Effects 0.000 description 1
- 230000003070 anti-hyperalgesia Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000004054 benzoquinones Chemical class 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- KQWGXHWJMSMDJJ-UHFFFAOYSA-N cyclohexyl isocyanate Chemical compound O=C=NC1CCCCC1 KQWGXHWJMSMDJJ-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 229940125542 dual agonist Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002085 enols Chemical group 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000002461 excitatory amino acid Effects 0.000 description 1
- 239000003257 excitatory amino acid Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000010575 fractional recrystallization Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000012203 high throughput assay Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000035859 hyperreflexia Effects 0.000 description 1
- 206010020745 hyperreflexia Diseases 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000005518 mononeuropathy Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000008555 neuronal activation Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000008055 nociceptive signaling Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FATBGEAMYMYZAF-KTKRTIGZSA-N oleamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(N)=O FATBGEAMYMYZAF-KTKRTIGZSA-N 0.000 description 1
- FATBGEAMYMYZAF-UHFFFAOYSA-N oleicacidamide-heptaglycolether Natural products CCCCCCCCC=CCCCCCCCC(N)=O FATBGEAMYMYZAF-UHFFFAOYSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000003614 peroxisome proliferator Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000006611 pharmacological activation Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
- C07C271/56—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/02—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from isocyanates with formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
本出願は、2011年8月19日に出願された米国仮特許出願第61/525,636号の優先権および利益を主張し、その開示の全てが引用により本明細書に組み込まれる。
本発明は、国立衛生研究所より与えられた助成金番号AA0l7538号、DA0l2413号、およびDA0l2447号のもとで、米国政府支援により創出された。米国政府は本発明に一定の権利を有する。
本発明は、脂肪酸アミド加水分解酵素(FAAH)の末梢に限局された阻害剤を製造および使用する方法を提供する。本発明は、FAAH活性を抑制する化合物を提供し、中枢神経系(CNS)外のアナンダミドレベルを増大させる。脳へのアクセスが比較的できないにもかかわらず、そのような化合物は、炎症の齧歯類モデルにおける持続痛を示す行動反応の軽減に有用である。本発明はまた、FAAHを阻害する方法ならびに、限定されないが、疼痛、炎症、免疫異常、皮膚炎、粘膜炎、末梢感覚ニューロンの過剰反応、神経皮膚炎、および過活動膀胱などの症状を治療するための方法も記載する。したがって、本発明はまた、末梢FAAHの選択的阻害が(CNSのFAAHとは対照的に)有効性をもたらす、症状を治療するための化合物、方法、および医薬組成物も提供する。
本明細書および添付の特許請求の範囲で用いられる場合、単数形「a」、「an」および「the」は、文脈上明白に別段の記載がない限り、複数を包含する。
本出願は、式Iの末梢に限局されたFAAH阻害剤を提供する。これらの阻害剤は、FAAH阻害活性を保持し、末梢に限局され、これは非常に有利であり、なぜなら、これらの阻害剤は哺乳類の対象において代謝される場合に反応性ベンゾキノンを実質的に形成しないからである。
本明細書中で記載される化合物に関するアッセイは、ハイスループットスクリーニングにしたがう。好ましいアッセイは、したがって、FAAHに対する阻害剤の結合またはオレオイルエタノールアミドもしくはアナンダミドなどの基質の加水分解によって生じる反応生成物(たとえば、脂肪酸アミドもしくはエタノールアミン)の放出を検出する。基質を標識して、放出された反応生成物の検出を促進することができる。特定の反応生成物の存在、非存在、または定量化に関するハイスループットアッセイは、当業者に周知である。したがって、たとえば米国特許第5,559,410号は、タンパク質についてのハイスループットスクリーニング法を開示し、米国特許第5,576,220号および同第5,541,061号は、リガンド/抗体結合についてのスクリーニングのハイスループット法を開示する。
末梢カンナビノイド受容体は疼痛開始の強力な阻害制御を発揮するが、この内因性鎮痛機序に通常関与する内因性カンナビノイドシグナルは解明されていない。エンドカンナビノイドアナンダミドの分解の一因となる酵素である脂肪酸アミド加水分解酵素(FAAH)の新しい末梢に限局された阻害剤である、下記実施例で記載される化合物URB937は、FAAH活性を抑制し、中枢神経系(CNS)外のアナンダミドレベルを増加させることが判明している。URB937が脳からの輸送系によって媒介される排出を驚くほど受けやすいことが判明したことは注目に値する。意外にも脳や脊髄に比較的アクセスできないが、URB937は、炎症および末梢神経傷害の齧歯類モデルにおける持続痛を示す行動反応を軽減し、侵害プロセッシング(nociceptive processing)に関与する脊髄領域での侵害刺激によって惹起されるニューロン活性化を抑制する。CB1受容体遮断はこれらの効果を妨げる。この結果は、末梢CB1受容体でのアナンダミド媒介性シグナル伝達が疼痛の情報のCNSへの伝達を制御することを示した。したがって、このゲーティングメカニズムを強化する相対的に脳非透過性のFAAH阻害剤は、疼痛療法に対する新規アプローチを提供する(あらゆる目的に関して、特にFAAH阻害剤をそれらの生物学的および薬剤学的特性、ならびに末梢に限局されたFAAH阻害剤一般の薬理学的特性について分析する方法に関して、その全体が参照によって本明細書中に組み込まれる、2010年7月28日に出願された米国仮特許出願第61/368,500号を参照のこと)。
本明細書中で記載される化合物および組成物は、末梢FAAH阻害が望ましい障害を治療するために有用である。そのような障害としては、疼痛、炎症、自己免疫異常、肥満、摂食障害、および食欲制御、代謝障害、脂肪肝およびぜんそくが挙げられるが、これらに限定されるものではない。本明細書中で記載されるある特定の組成物および化合物は、パラ−ヒドロキシビフェニル部分の肝臓酸化によって毒性ベンゾキノン部分を形成する可能性がある化合物URB937などの末梢に限局されたFAAH阻害剤に勝る顕著な利点を提供する。
本発明はさらに、前述の末梢に限局されたFAAH阻害化合物の医薬組成物も提供する。「組成物」という用語は、医薬組成物における場合、活性成分(複数可)を含む生成物、および担体を構成する不活性成分(複数可)、ならびに任意の2以上の成分の組み合わせ、複合体形成もしくは凝集から、または1以上の成分の解離から、または1以上の成分の他の種類の反応もしくは相互作用から、直接的もしくは間接的に生じる任意の生成物を含むことが意図される。したがって、本発明の医薬組成物は、本発明の化合物と薬剤的に許容される担体とを混合することによって作製される任意の組成物を包含する。「医薬組成物」という用語は、動物またはヒトを包含する対象における製薬学的用途に好適な組成物を意味する。医薬組成物は、一般的に、有効量の活性剤および薬学的に許容可能な担体を含む。
本明細書中で記載する化合物は、医薬組成物として、以下の経路のうちの1つによって投与することができる:経口、全身性(たとえば、経皮的、鼻内もしくは坐薬による)または非経口(たとえば、筋肉内、静脈内もしくは皮下)。組成物は、錠剤、ピル、カプセル、半固体、粉末、持続放出処方、溶液、懸濁液、エリキシル、エアゾル、または任意の他の適切な組成物の形態をとることができ、一般的に、少なくとも1つの薬剤的に許容される賦形剤と組み合わせた本明細書中で記載される化合物から構成される。許容される賦形剤は、非毒性であり、投与を助け、活性成分の治療的有用性に悪影響を及ぼさない。そのような賦形剤は、任意の固体、液体、半固体または、エアゾル組成物の場合は、当業者が一般的に利用可能なガス状賦形剤であり得る。
a.疼痛の制御
いくつかの実施形態において、本明細書中で記載する化合物を投与して、対象における疼痛を緩和または治療することができる。治療は予防的または治療的であり得る。治療をヒト対象に実施することができる。本発明の化合物および組成物は、疼痛の重篤度または頻度または程度を軽減する目的のためだけに投与することができる。治療は別の鎮痛薬または抗炎症薬との併用療法で実施することができる。いくつかの実施形態において、疼痛は、ポスト三叉神経痛(post trigeminal neuralgia)、神経因性腰痛、末梢または多発性神経因性疼痛、複合性局所疼痛症候群(灼熱痛および反射性交感神経性ジストロフィー)、糖尿病性ニューロパシー、中毒性ニューロパシー、および化学療法薬に起因する慢性ニューロパシーからなる群から選択される神経因性疼痛であり得る。他の実施形態において、疼痛は、腎臓および肝臓疝痛または線維筋痛である。いくつかの神経因性疼痛実施形態において、神経系の原発病巣または機能不全は、対象の神経に対する機械的傷害に起因する。さらなる実施形態において、機械的傷害は、対象における神経の圧迫、神経の切断、灼熱痛、脊髄傷害、術後痛、幻肢痛、または瘢痕形成によるものである。
いくつかの実施形態において、式Iの化合物を投与して、対象における炎症を緩和することができる。治療は予防的または治療的であり得る。治療はヒト対象に実施することができる。本発明の化合物および組成物は、炎症の重篤度または頻度または程度を軽減する目的のためだけに投与することができる。治療は別の鎮痛薬または抗炎症薬との併用療法で投与することができる。
a.実施例1
抗侵害受容活性の化合物をスクリーニングする方法:抗侵害受容性作用について、FAAH阻害剤をスクリーニングする方法は、当業者に周知である。例えば、試験化合物は、マウスホットプレート試験およびマウスホルマリン試験において対象動物に投与され得、組織の熱損傷または化学損傷に対する侵害受容反応が測定される。抗侵害受容活性をスクリーニングする方法を教示した米国特許第6,326,156号も参照のこと。Cravatt et al. Proc. Natl. Acad. Sci. U.S.A. 98:9371-9376 (2001)を参照のこと。
末梢に限局されたFAAH阻害剤の薬理学的特性:
機械的痛覚過敏−機械的痛覚過敏は、足を与えられた一定の機械的圧力から背面へと逃避する秒単位の潜時(latency)を測定することにより決定した。機械力を与えるため、円錐先端(直径3mm)を備えた15gの目盛つきガラス円柱棒(直径10mm)を使用した。スタンドに取り付けた2つの環の間に体重を垂直に吊るし、垂直方向に自由に動くようにした。180秒のカットオフタイム(cutoff time)を用いた。逃避閾値を、炎症を起こした同側の足について、経口薬物投与後の異なる時点で測定した。各実験群には、6匹のマウスが含まれた。各マウスでは3種類の評価を行い、結果として合計18測定行った。熱性痛覚過敏を、記載のように(Hargreaves, K., Dubner, R., Brown, F., Flores, C., & Joris, J., A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32 (1), 77-88 (1988))、足底試験装置(Ugo Basile, Italy)を用いて、後足を、足底面に印加した放射熱の集束ビーム(熱強度:赤外線放射3.0)から逃避する潜時を測定し評価した。カットオフタイムは30秒に設定した。逃避潜時を、炎症を起こした同側の足について、経口薬物投与後の異なる時点で測定した。各実験群には、6匹のマウスが含まれた。各マウスでは3種類の評価を行い、結果として合計18測定行った。
[3−(3−カルバモイルフェニル)−5−ヒドロキシ−フェニル]N−シクロヘキシルカルバメート(化合物1)の合成。化合物1を、以下のスキームに記載のように合成した:
末梢でのFAAH阻害能についての、本発明による化合物と他の末梢に限局されたFAAH阻害剤との比較。上述のURB937について記載されたものと同様のFAAH抑制生物アッセイ方法を使用して(Clapper et al. Nature Neuroscience 13:1265-70 (2010)も参照のこと)、(当該FAAH生物アッセイ方法に関する参照により本明細書に組み込まれる)、投与後の化合物の肝臓およびCNSのFAAH阻害活性を、URB937と比較した。具体的には、(1)FAAHアッセイを使用して、IC50値をin vitroで得た。(2)肝臓および(3)脳のin vivo FAAH抑制値の百分率を以下のように測定した。マウスに各化合物の1mg/kg用量を腹腔内経路により投与し,投与2時間後に屠殺した。組織を採取し、FAAH活性を、FAAHアッセイを使用して、組織抽出物(膜画分)でex vivo測定した。データを以下の表1で報告する。
式Iの化合物の、末梢に限局されたFAAH阻害剤としての活性は、一部、p−ヒドロキシフェニル部分の極性に基づいて見出された。この部分は、URB937の末梢隔離(peripheral segregation)への貢献因子(contributor)、モデル末梢に限局されたFAAH阻害剤であることが見いだされた。表3では、R40置換基が弱い極性または無極性の類似化合物、例えば1c、1dおよび1eが、マウスでの全身投与後の脳に侵入していることが見出され、一方で、R40が極性をもつアミノ基からなる類似化合物、例えば化合物1fは、概して排除されていることが見出されたことが、示される。
Claims (22)
- 式:
R2およびR3は独立して水素および置換または非置換(C1−C3)アルキルからなる群から選択され;
各R4は独立して水素および置換または非置換(C1−C3)アルキルからなる群から選択され、nは0から4までの整数であり;
R6は非置換もしくは置換シクロヘキシル、シクロペンチル、シクロブチルまたはテトラヒドロピラン−4−イルであり、
1)R 1 が水素であり、かつR 5 がカルボキシおよびその生理的に加水分解可能なエステル、並びにヒドロキシル−(C 1 −C 3 )アルキルおよびその生理的に加水分解可能なエステルからなる群から選択されるか、または
2)R 1 がヒドロキシおよびその生理的に加水分解可能なエステル、カルボキシおよびその生理的に加水分解可能なエステル、ヒドロキシル−(C 1 −C 3 )アルキルおよびその生理的に加水分解可能なエステル、および−NR 7 R 8 からなる群から選択され;R 7 およびR 8 は独立して水素および(C 1 −C 3 )アルキルから選択され、かつ、R 5 が水素である)
を有する化合物、またはその薬学的に許容可能な塩。 - R 1 が水素であり、かつR 5 がカルボキシおよびその生理的に加水分解可能なエステル、並びにヒドロキシル−(C 1 −C 3 )アルキルおよびその生理的に加水分解可能なエステルから選択される、請求項1に記載の化合物。
- R 1 がヒドロキシおよびその生理的に加水分解可能なエステル、カルボキシおよびその生理的に加水分解可能なエステル、ヒドロキシル−(C 1 −C 3 )アルキルおよびその生理的に加水分解可能なエステル、および−NR 7 R 8 からなる群から選択され;R 7 およびR 8 は独立して水素または(C 1 −C 3 )アルキルから選択され、かつ、R 5 が水素である、請求項1に記載の化合物。
- R2およびR3がそれぞれHである、請求項1〜3のいずれか一項に記載の化合物。
- nが0または1である、請求項1〜4のいずれか一項に記載の化合物。
- R 5 がCH 2 OHである、請求項1〜5のいずれか一項に記載の化合物。
- R 5 がCOOHである、請求項1〜5のいずれか一項に記載の化合物。
- R6が非置換シクロヘキシル、シクロペンチルまたはシクロブチルである、請求項1〜7のいずれか一項に記載の化合物。
- R 6 が非置換シクロヘキシルである、請求項1〜7のいずれか一項に記載の化合物。
- 前記生理的に加水分解可能なエステルが、式−OC(O)R10、−CH2OC(O)R10または−CH2CH2OC(O)R10であり、式中、R10が置換または非置換ヒドロカルビルである、請求項1〜9のいずれか一項に記載の化合物。
- R1が−C(O)OR10であり、R10が水素または置換もしくは非置換ヒドロカルビルである、請求項1〜9のいずれか一項に記載の化合物。
- 化合物が以下の構造:
- 化合物が以下の構造:
- 化合物が以下の構造:
- 化合物が以下の構造:
- 請求項1〜15のうちいずれか1項に記載の化合物を含む、医薬組成物。
- 請求項1〜15のうちいずれか1項に記載の化合物を含む医薬組成物であって、末梢脂肪酸アミド加水分解酵素(FAAH)の阻害を必要とする哺乳類でFAAHを阻害するための医薬組成物。
- 末梢脂肪酸アミド加水分解酵素(FAAH)を選択的に阻害する医薬組成物であって、前記組成物が、請求項1〜15のうちいずれか1項に記載の化合物を含む、医薬組成物。
- 疼痛、炎症、および免疫異常から選択される症状を治療する医薬組成物であって、前記組成物が、請求項1〜15のうちいずれか1項に記載の化合物を含む、医薬組成物。
- 請求項1〜15のうちいずれか1項に記載の化合物を含む医薬組成物であって、アナンダミド、オレオイルエタノールアミド(OEA)、パルミトイルエタノールアミド(PEA)、またはステアロイルエタノールアミド(SEA)の末梢レベルを哺乳類において増加させるための医薬組成物。
- 皮膚炎、粘膜炎、末梢感覚ニューロンの過剰反応、神経皮膚炎、過活動膀胱、咳の疼痛および/または炎症、並びに咳から選択される症状を治療するための、創傷もしくは組織傷害の治癒速度および/または質を増進するための、または、腸もしくは胃に対する傷害の治癒速度および/または質を増進するための医薬組成物であって、前記組成物が請求項1〜15のうちいずれか1項に記載の化合物を含む、医薬組成物。
- 薬学的に許容可能な賦形剤をさらに含む、請求項16〜21のいずれか一項に記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161525636P | 2011-08-19 | 2011-08-19 | |
US61/525,636 | 2011-08-19 | ||
PCT/US2012/051478 WO2013028570A2 (en) | 2011-08-19 | 2012-08-17 | Meta-substituted biphenyl peripherally restricted faah inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014527532A JP2014527532A (ja) | 2014-10-16 |
JP2014527532A5 JP2014527532A5 (ja) | 2015-10-01 |
JP6092870B2 true JP6092870B2 (ja) | 2017-03-08 |
Family
ID=47747054
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014526261A Active JP6092870B2 (ja) | 2011-08-19 | 2012-08-17 | メタ置換ビフェニル末梢に限局されたfaah阻害剤 |
Country Status (13)
Country | Link |
---|---|
US (1) | US9745255B2 (ja) |
EP (1) | EP2744778B1 (ja) |
JP (1) | JP6092870B2 (ja) |
KR (1) | KR102079404B1 (ja) |
CN (1) | CN104203906B (ja) |
AU (1) | AU2012299060B2 (ja) |
BR (1) | BR112014003886B1 (ja) |
CA (1) | CA2844812C (ja) |
DK (1) | DK2744778T3 (ja) |
ES (1) | ES2708723T3 (ja) |
HK (1) | HK1198644A1 (ja) |
MX (1) | MX354772B (ja) |
WO (1) | WO2013028570A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006001567A1 (en) * | 2004-06-24 | 2006-01-05 | Bioleaders Corporation | Poly-gamma-glutamic acid-vitamin complex and use thereof |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6092870B2 (ja) | 2011-08-19 | 2017-03-08 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | メタ置換ビフェニル末梢に限局されたfaah阻害剤 |
WO2014023325A1 (en) * | 2012-08-06 | 2014-02-13 | Fondazione Istituto Italiano Di Tecnologia | Multitarget faah and cox inhibitors and therapeutical uses thereof |
EP3988540A1 (en) | 2014-04-07 | 2022-04-27 | The Regents of the University of California | Inhibitors of fatty acid amide hydrolase (faah) enzyme with improved oral bioavailability and their use as medicaments |
JP6824270B2 (ja) | 2015-08-11 | 2021-02-03 | アイシュー メディシンズ ベスローテン フェンノートンシャップ | 生物活性親油性化合物を有するpeg化脂質ナノ粒子 |
US10702487B2 (en) | 2017-08-19 | 2020-07-07 | Frimline Private Limited | Pharmaceutical composition for prevention of diet induced obesity |
PH12018000227A1 (en) | 2017-09-05 | 2019-03-11 | Frimline Private Ltd | A pharmaceutical composition for improving or preventing progression of chronic kidney disease |
SG11202107213WA (en) * | 2019-01-10 | 2021-07-29 | Travecta Therapeutics Pte Ltd | Anandamide compounds |
CA3186853A1 (en) * | 2020-07-23 | 2022-01-27 | John Mansell | Compositions and methods for treating pain and anxiety disorders |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4325889A (en) | 1978-08-04 | 1982-04-20 | Bayer Aktiengesellschaft | Process for the preparation of 1-amino-8-naphthol-3,6-disulphonic acid (H-acid) |
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US4511503A (en) | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
US5541061A (en) | 1992-04-29 | 1996-07-30 | Affymax Technologies N.V. | Methods for screening factorial chemical libraries |
EP0604289B1 (fr) | 1992-12-17 | 1997-09-24 | Valeo Systemes D'essuyage | Procédé et dispositif d'alimentation d'un moteur électrique d'entrainement d'un bras d'essuie-glace de véhicule automobile |
US5576220A (en) | 1993-02-19 | 1996-11-19 | Arris Pharmaceutical Corporation | Thin film HPMP matrix systems and methods for constructing and displaying ligands |
US6271015B1 (en) | 1995-06-12 | 2001-08-07 | The Scripps Research Institute | Fatty-acid amide hydrolase |
CA2206192A1 (en) | 1996-06-13 | 1997-12-13 | F. Hoffmann-La Roche Ag | Modulation of lc132 (opioid-like) receptor function |
WO1998024443A1 (en) | 1996-12-02 | 1998-06-11 | Merck Sharp & Dohme Limited | Use of nk-1 receptor antagonists for treating bipolar disorders |
GB9701453D0 (en) | 1997-01-24 | 1997-03-12 | Leo Pharm Prod Ltd | Aminobenzophenones |
FR2758723B1 (fr) | 1997-01-28 | 1999-04-23 | Sanofi Sa | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
TW492882B (en) | 1997-11-28 | 2002-07-01 | Caleb Pharmaceuticals Inc | Cholinergic antagonist plaster composition |
KR100523184B1 (ko) | 1998-02-26 | 2005-10-24 | 악조 노벨 엔.브이. | 아제티딘 및 피롤리딘의 유도체 |
CA2330681C (en) | 1998-05-29 | 2008-08-26 | Andrea Giuffrida | Control of pain with endogenous cannabinoids |
US7897598B2 (en) | 1998-06-09 | 2011-03-01 | Alexandros Makriyannis | Inhibitors of the anandamide transporter |
US20030134894A1 (en) | 1999-04-07 | 2003-07-17 | Daniele Piomelli | Methods of treating mental diseases, inflammation and pain |
US6261595B1 (en) | 2000-02-29 | 2001-07-17 | Zars, Inc. | Transdermal drug patch with attached pocket for controlled heating device |
NZ570989A (en) | 2002-05-16 | 2010-01-29 | Sepracor Inc | Amines that inhibit a mammalian anandamide transporter, and methods of use thereof |
FR2842808B1 (fr) | 2002-07-25 | 2004-09-10 | Sod Conseils Rech Applic | Nouveaux derives d'arylimidazoles, leur preparation et leurs applications therapeutiques |
JP4515911B2 (ja) | 2002-10-07 | 2010-08-04 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | アナンダミド加水分解の遮断による不安の調節 |
FR2850377B1 (fr) | 2003-01-23 | 2009-02-20 | Sanofi Synthelabo | Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique |
FR2866888B1 (fr) | 2004-02-26 | 2006-05-05 | Sanofi Synthelabo | Derives de alkylpiperazine- et alkylhomopiperazine- carboxylates, leur preparation et leur application en therapeutique |
US20070155707A1 (en) | 2005-12-29 | 2007-07-05 | Kadmus Pharmaceuticals, Inc. | Ionizable inhibitors of fatty acid amide hydrolase |
WO2008067196A2 (en) | 2006-11-16 | 2008-06-05 | The Regents Of The University Of California | Methods for identifying inhibitors of solute transporters |
CA2674359A1 (en) * | 2006-11-20 | 2008-05-29 | N.V. Organon | Metabolically-stabilized inhibitors of fatty acid amide hydrolase |
TW200948805A (en) | 2008-03-07 | 2009-12-01 | Sigma Tau Ind Farmaceuti | Enol carbamate derivatives as modulators of fatty acid amide hydrolase |
PL2488486T3 (pl) | 2009-10-13 | 2020-01-31 | Ligand Pharmaceuticals Inc. | Małocząsteczkowe związki mimetyczne hematopoetycznego czynnika wzrostu i ich zastosowania |
JP5981429B2 (ja) | 2010-07-28 | 2016-08-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 末梢に制限されたfaah阻害剤 |
WO2012167133A2 (en) | 2011-06-01 | 2012-12-06 | The Regents Of The University Of California | Inhibitors of anandamide transport and their therapeutic uses |
JP6092870B2 (ja) | 2011-08-19 | 2017-03-08 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | メタ置換ビフェニル末梢に限局されたfaah阻害剤 |
EP3988540A1 (en) | 2014-04-07 | 2022-04-27 | The Regents of the University of California | Inhibitors of fatty acid amide hydrolase (faah) enzyme with improved oral bioavailability and their use as medicaments |
-
2012
- 2012-08-17 JP JP2014526261A patent/JP6092870B2/ja active Active
- 2012-08-17 ES ES12826376T patent/ES2708723T3/es active Active
- 2012-08-17 BR BR112014003886-4A patent/BR112014003886B1/pt active IP Right Grant
- 2012-08-17 MX MX2014001966A patent/MX354772B/es active IP Right Grant
- 2012-08-17 KR KR1020147007303A patent/KR102079404B1/ko active IP Right Grant
- 2012-08-17 CA CA2844812A patent/CA2844812C/en active Active
- 2012-08-17 AU AU2012299060A patent/AU2012299060B2/en active Active
- 2012-08-17 EP EP12826376.1A patent/EP2744778B1/en active Active
- 2012-08-17 DK DK12826376.1T patent/DK2744778T3/en active
- 2012-08-17 CN CN201280051448.5A patent/CN104203906B/zh active Active
- 2012-08-17 WO PCT/US2012/051478 patent/WO2013028570A2/en active Application Filing
-
2014
- 2014-02-18 US US14/183,073 patent/US9745255B2/en active Active
- 2014-12-01 HK HK14112102.4A patent/HK1198644A1/xx unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006001567A1 (en) * | 2004-06-24 | 2006-01-05 | Bioleaders Corporation | Poly-gamma-glutamic acid-vitamin complex and use thereof |
Also Published As
Publication number | Publication date |
---|---|
DK2744778T3 (en) | 2019-03-04 |
US9745255B2 (en) | 2017-08-29 |
CN104203906B (zh) | 2018-03-13 |
ES2708723T3 (es) | 2019-04-10 |
JP2014527532A (ja) | 2014-10-16 |
BR112014003886A8 (pt) | 2018-01-23 |
CA2844812C (en) | 2019-10-22 |
EP2744778A2 (en) | 2014-06-25 |
MX2014001966A (es) | 2015-04-08 |
CN104203906A (zh) | 2014-12-10 |
NZ622480A (en) | 2016-05-27 |
WO2013028570A3 (en) | 2013-04-18 |
AU2012299060A1 (en) | 2014-04-03 |
EP2744778B1 (en) | 2019-01-16 |
AU2012299060B2 (en) | 2017-06-01 |
US20140288170A1 (en) | 2014-09-25 |
CA2844812A1 (en) | 2013-02-28 |
BR112014003886A2 (pt) | 2017-03-21 |
BR112014003886B1 (pt) | 2022-04-19 |
HK1198644A1 (en) | 2015-05-22 |
KR102079404B1 (ko) | 2020-02-19 |
EP2744778A4 (en) | 2015-04-08 |
WO2013028570A2 (en) | 2013-02-28 |
KR20150100485A (ko) | 2015-09-02 |
MX354772B (es) | 2018-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6092870B2 (ja) | メタ置換ビフェニル末梢に限局されたfaah阻害剤 | |
Sherwood et al. | Synthesis and biological evaluation of tryptamines found in hallucinogenic mushrooms: norbaeocystin, baeocystin, norpsilocin, and aeruginascin | |
CA2843265C (en) | Peripherally restricted faah inhibitors | |
JP6989505B2 (ja) | Malt1阻害剤およびその使用 | |
Ponzano et al. | Synthesis and structure–activity relationship (SAR) of 2-methyl-4-oxo-3-oxetanylcarbamic acid esters, a class of potent N-acylethanolamine acid amidase (NAAA) inhibitors | |
KR20050088992A (ko) | 아난드아미드 가수분해 차단을 통한 불안감의 조절 | |
US9353075B2 (en) | Disubstituted beta-lactones as inhibitors of N-acylethanolamine acid amidase (NAAA) | |
EP2745876A1 (en) | Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives | |
EP3119768B1 (en) | 3,4-bromo or -sulfonate substituted 1h-pyrrole-2,5-dione derivatives as type iii deiodinase (dio3) inhibitors for treating depressions and cancer | |
JP2008533122A (ja) | 新規なチロシン誘導体 | |
EA022158B1 (ru) | Модуляторы активности гидролазы амидов жирных кислот | |
Elumalai et al. | Development of potent cholinesterase inhibitors based on a marine pharmacophore | |
NZ622480B2 (en) | Meta-substituted biphenyl peripherally restricted faah inhibitors | |
US10537545B2 (en) | Ceramide derivatives as anticancer agents | |
WO2024044751A2 (en) | Peroxiredoxin 3 inhibitors and methods of use for treating cancer | |
US20120108667A1 (en) | Hydroxy ceramides and analogs thereof and their use for preventing or treating cancer | |
Singh Grewal et al. | Synthesis, Docking and Evaluation of Phenylacetic Acid and Trifluoro-methylphenyl Substituted Benzamide Derivatives as Potential PPARδ Agonists | |
Astarita et al. | JPET# 105221 | |
KR20080075922A (ko) | 칼슘 채널 차단제로서의 디벤젠 유도체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150814 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150814 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160325 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160405 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160630 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160905 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161005 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170110 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170209 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6092870 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |